US Drugmaker Amgen To Invest $200 Million In India

Photo: facebook.com/amgenbiotech

India-West News Desk

NEW DELHI – U.S. drugmaker Amgen plans to invest approximately $200 million this year in its new technology center located in southern India, with additional investments anticipated, CEO Robert Bradway announced during the site’s inauguration on February 24.

Last year, Amgen revealed its intentions to establish a “technology and innovation” center in India aimed at leveraging AI and data science to enhance the development of new medicines.

“We have wanted for a long time to expand Amgen’s presence in India, and that time has come. Amgen is investing an initial $200 million in this center in 2025 and plans to make additional significant investments in future years,” Bradway stated.

The facility in Hyderabad is expected to employ around 2,000 individuals by the end of the year, with approximately 300 employees already on board. Amgen joins numerous global pharmaceutical companies looking to strengthen their footprint in India, often referred to as the “pharmacy of the world,” said Reuters.

Additionally, India and the U.S. agreed this month to commence discussions on an early trade deal and to address their ongoing tariff dispute following talks between President Donald Trump and Prime Minister Narendra Modi. Trump has indicated plans to impose “25% or higher” tariffs on pharmaceutical imports, a move that could significantly impact Indian firms, as many generic drug manufacturers consider the U.S. their largest market Reuters reports.